Pilot Study of CannabigerolCannabidiol Oil for Treating Chemotherapy-Induced Peripheral Neuropathy in Adults

What this Trial Is About

This research aims to evaluate the safety, feasibility, and preliminary effectiveness of a commercially available cannabigerol CBG and cannabidiol CBD oil in adults who have chemotherapy-induced peripheral neuropathy CIPN after completing platinum-based chemotherapy for gastrointestinal cancers. The study builds on earlier preclinical work showing that CBG and CBD may reduce nerve pain in animal models, addressing the need for better treatments for CIPN, which current therapies often do not manage well. Participants will receive a high-CBGCBD hemp oil extract containing small amounts of cannabichromene CBC, taken under the tongue twice daily for 12 weeks. The dosing starts with 0.5 mL twice daily during the first week, increasing to 1 mL twice daily for the remaining 11 weeks. The treatment period is divided into three 4-week cycles, with weekly remote safety phone calls and follow-up calls one month after treatment ends to monitor safety and adherence. Throughout the study, participants will complete symptom assessments, physical and mental health evaluations, and provide blood samples to measure cannabinoid levels. Researchers will monitor safety, tolerability, treatment adherence, changes in neuropathy symptoms, physical and mental function, and cannabinoid blood levels over the 12-week treatment period. The study aims to learn if this oil is safe, feasible to use, and helpful for managing CIPN symptoms.

CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy